bi-907828
boehringer ingelheim
['#gi', 'bi 907828', 'pancsm', 'sarcoma', 'gism', 'solid tumor']
at #esmo22 we spoke to who discussed results of a phase i dose-escalation study of bi 907828, an mdm2 p53 antagonist, in pts with solid tumors watch the full interview here: #gism #pancsm #sarcoma
The Video Journal of Oncology is dedicated to providing trusted information to improve knowledge, understanding and awareness of cancer. Intended for HCPs only.